Speaker Bios

**Christos Argyropoulos, MD**

Dr. Argyropoulos is the Chief of Nephrology at the University of New Mexico School of Medicine, Department of Internal Medicine and early adopter of SGLT2 inhibitors in clinical practice. Dr. Argyropoulos conducts research in the areas of data science, nephrology, systems biology, and bioinformatics. He has a particular interest in predictive biomarkers and systems biology modeling of diabetic kidney disease, epidemiology, and outcomes in patients with CKS or ESRD and the introduction of novel statistical methods for the analysis of large datasets to answer clinically relevant questions.

**Frank (Chip) Brosius, MD**

Dr. Brosius is a professor of medicine at the University of Arizona, and is an active professor emeritus at the University of Michigan. His research focuses on identification of new targets for treatment of diabetic kidney disease (DKD). One such target identified by Dr. Brosius and colleagues was the JAK/STAT signaling pathway. A phase 2 clinical trial, co-led by Dr. Kathy Tuttle and Dr. Brosius showed that a JAK inhibitor led to reduced albuminuria in patients with DKD. He currently is a principal investigator on a multi-PI NIH R24 grant to identify additional targets for intervention in kidney, nerve and eye complications of diabetes and has additional NIH/NIDDK funding. He is also involved in a number of clinical studies targeting DKD and other chronic kidney diseases. He currently chairs the NIH study section, Pathobiology of Kidney Disease. He has served and continues to serve on multiple committees and working groups related to his clinical and research interests with the American Society of Nephrology, National Kidney Foundation, American Heart Association and American Diabetes Association.
David Cherney, MD CM, PhD, FRCP(C)

Following his clinical training in Nephrology, Dr. Cherney completed his PhD in human renal physiology at the Institute of Medical Science, University of Toronto in 2008. He is currently Professor in the Department of Medicine, University of Toronto and a Clinician Scientist at the University Health Network and Mount Sinai Hospitals, where he is director of the Renal Physiology Laboratory. He is supported by the Canadian Institutes of Health Research, the JDRF, the Heart and Stroke Richard Lewar Centre of Excellence, the Heart and Stroke Foundation of Canada and the Banting and Best Diabetes Centre. He is also supported by a Department of Medicine, University of Toronto Merit Award. Dr. Cherney’s research program focuses on physiological factors that initiate renal disease in patients with diabetes, such as renal hyperfiltration and inflammation, and the role of the cardiorenal axis in diabetes. His research group is also involved in early and late phase clinical trials in the cardiorenal-metabolic field, including several primary renal outcome trials in patients with and without diabetes. Dr. Cherney’s research program is closely aligned with his integrated and multidisciplinary cardiac-renal-endocrine clinic at the University Health Network, which maintains a strong emphasis on the prevention of diabetic nephropathy and cardiovascular disease. In 2019, he received the American Society of Nephrology (ASN) Distinguished Researcher Award for outstanding contributions to nephrology. In 2019 he also received the Diabetes Canada/CIHR - Institute of Nutrition Diabetes and Metabolism (INMD) Young Scientist Award.

Patrick O. Gee, Sr., PhD., JLC

Dr. Gee graduated from the American University School of Public Affairs in 2012 with a Doctor of Philosophy in Justice, Law, & Criminology. Patrick is a former Peritoneal/Hemodialysis patient due to suffering from Diabetic Kidney Disease. Patrick has been a Post-Kidney Transplant Recipient since April 2017. Patrick is also a retired Major/Chief of Security from the Virginia Department of Corrections; and currently serves as the Founder & CEHD of iAdvocate, Inc., a non-profit Faith-based Health & Wellness organization. He is also an Ordained Minister at Mountain Movers Ministry in Richmond, VA.

As a Patient Representative for the Diabetes Kidney Disease-Collaborative Task Force and an advocate for those living with chronic kidney disease and the morbid conditions that contribute to this disease, such as diabetes, cardiovascular disease, hypertension, and obesity, Patrick uses his personal experiences to teach, coach, mentor, and educate others on how best to manage their outcomes. He also ensures that underserved, undervalued, and disenfranchised communities of color have a voice in their quality of life and equitable healthcare access.
Joanna Q. Hudson, PharmD, BCPS, FASN, FCCP, FNKF

Dr. Hudson is a tenured Professor in the Department of Clinical Pharmacy and Translational Science and the Department of Medicine (Division of Nephrology) at the University of Tennessee (UT) Health Science Center and a Clinical Pharmacist specializing in nephrology at Methodist University Hospital in Memphis, TN. Prior to joining the faculty at UT, she completed a 2-year Nephrology fellowship at Virginia Commonwealth University-Medical College of Virginia. Her clinical practice is focused on the management of patients with both acute and chronic kidney disease through her activities at MUH and the outpatient dialysis centers. Her teaching and research interests focus on drug disposition in individuals with chronic kidney disease and during renal replacement therapy. She has been recognized as a Fellow of the American Society of Nephrology, the American College of Clinical Pharmacy and the National Kidney Foundation.

Alan S. Kliger, MD

Dr. Kliger is a Clinical Professor of Medicine, Yale University School of Medicine. He is a member of the Standing Renal Committee for the National Quality Forum, and chairs the Nephrologists Transforming Dialysis Safety initiative, a national partnership between the Centers for Disease Control and Prevention (CDC) and the American Society of Nephrology (ASN). He served formerly as Senior Vice President Medical Affairs, Chief Quality Officer, Yale New Haven Health System and Senior Vice President, Chief Medical Officer, Hospital of Saint Raphael, New Haven Connecticut. He is a past president of the Renal Physicians Association, and serves on its Quality, Safety and Accountability Committee. He is a past president of the Forum of ESRD Networks. He served as chair of the steering committee for the NIH Frequent Hemodialysis Study, a national prospective randomized study of in-center daily and home nocturnal hemodialysis, and currently chairs the steering committee for an NIH/NIDDK Consortium on Novel Therapies for Hemodialysis Patients.

Amy Mottl, MD, MPH, FASN

Dr. Mottl is an Associate Professor of Medicine in the Division of Nephrology and Hypertension at the UNC School of Medicine.

Dr. Mottl’s research has involved investigation of genetic and epidemiologic risk factors of chronic kidney disease, with an emphasis on diabetic kidney disease. She is especially interested in pathogenic mechanisms of diabetic nephropathy and how these may vary between those with and without proteinuria. She is being funded through 2017, by a career development award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to study whether there are different pathologic and clinical manifestations of diabetes on the kidney and how these relate to
diabetic complications of the eye. Dr. Mottl is a renal consultant to the multicenter, NIH and CDC funded study: ‘SEARCH for Diabetes in Youth’ which is an epidemiologic cohort of children with type 1 or 2 diabetes. One of the fundamental aims of this study is to track the incidence, risk factors and natural history of microvascular complications of diabetes diagnosed during childhood. Dr. Mottl’s long-term goal is to elucidate pathogenic mechanisms in diabetic microvascular complications for the purpose of targeting novel therapies.

Jay H. Shubrook, DO

Dr. Shubrook is a board certified Family Physician and a Fellowship Trained Diabetologist. He serves as a Professor in Primary Care Department at Touro University California and also serves as the Director of Clinical Research and Diabetes Services at this institution. His research is on early intervention of type 2 diabetes and his professional interest is to better train the primary care work force to manage diabetes. He is the past chair of the Primary Care Advisory Committee of the American Diabetes Association. He is the Associate Editor of Clinical Diabetes. He is honored to be working with you today.

Katherine R. Tuttle, MD, FASN, FACP, FNKF

Dr. Tuttle is Executive Director for Research at Providence Health Care, Co-Principal Investigator of the Institute of Translational Health Sciences and Professor of Medicine at the University of Washington. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University School of Medicine in Chicago, Illinois. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis, Missouri. Her nephrology fellowship training was performed at University of Texas Health Science Center in San Antonio, Texas.

Dr. Tuttle’s major research interests are in clinical and translational science for diabetes and chronic kidney disease. She has published over 250 original research contributions and served two terms as Associate Editor for the Clinical Journal of the American Society of Nephrology and the American Journal of Kidney Disease. Dr. Tuttle has received many honors and awards including the Medal of Excellence from the American Association of Kidney Patients, Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two Outstanding Clinical Faculty Awards at the University of Washington. Dr. Tuttle served on the Board of Directors for the Kidney Health Initiative and has chaired numerous kidney and diabetes related working groups and committees for organizations including the NIDDK/NIH, the National Kidney Foundation, the American Society of Nephrology, the International Society of Nephrology, and the American Diabetes Association.